Ezetimibe
Ezetimibe blocks intestinal cholesterol absorption via the NPC1L1 transporter, lowering ApoB about 15-20% as monotherapy and producing additive effects on top of a statin. IMPROVE-IT proved this translates to fewer cardiovascular events.
Cholesterol absorption inhibitorPrescription requiredEvidence A
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
Ezetimibe is the quietest workhorse in lipid management. Acting at the gut rather than the liver, it reduces dietary and biliary cholesterol uptake by inhibiting NPC1L1, the same transporter whose loss-of-function mutations protect humans from coronary disease (Stitziel et al., NEJM 2014). Monotherapy lowers LDL-C and ApoB by roughly 18%, but its real power is additivity: pairing low-dose rosuvastatin (5 mg) with ezetimibe (10 mg) often achieves ApoB reductions equivalent to high-dose statin monotherapy with fewer muscle complaints. IMPROVE-IT (NEJM 2015) demonstrated that adding ezetimibe to simvastatin after acute coronary syndrome reduced major cardiovascular events, validating the "lower is better" hypothesis through a non-statin mechanism. Side effects are minimal and the drug is now generic and inexpensive. For longevity-focused men chasing ApoB under 60 mg/dL, ezetimibe is often the cleanest second agent.
Uses
Label uses (approved)
- Primary hypercholesterolemia (mono- or combination therapy)
- Homozygous familial hypercholesterolemia
- Homozygous sitosterolemia
- Secondary prevention of ASCVD when added to statin
Off-label (educational only)
- Statin-intolerant patients seeking ApoB reduction — Monotherapy lowers LDL-C ~18% and ApoB ~15% without myopathy risk
- Adjunct when statin alone fails to reach ApoB target — IMPROVE-IT showed additive event reduction with ezetimibe plus simvastatin
Dosing
Label dose
10 mg orally once daily
Off-label / biohacker dose
10 mg daily (no off-label dose range; the drug has a flat dose-response)
Titration: No titration needed. Full effect within 2 weeks. Recheck lipids at 4-6 weeks. Often combined with low-dose rosuvastatin (e.g., rosuvastatin 5 mg + ezetimibe 10 mg) for additive ApoB lowering with minimal side effects.
When to take: Any time of day, with or without food. Separate from bile acid sequestrants by 2 hours before or 4 hours after.
Side effects & warnings
Common
- Diarrhea
- Upper respiratory symptoms
- Fatigue
- Arthralgia
Uncommon but serious
- Myalgia (less than statins)
- Mild ALT elevation when combined with statin
- Cholelithiasis (rare)
Serious warnings
Hepatotoxicity is rare; avoid in moderate to severe hepatic impairment. Rare angioedema and pancreatitis reported in post-marketing surveillance.
Biomarkers affected
Monitoring
Lipid panel + ApoB at 4-6 weeks then annually; ALT if combined with statin
The honest risk picture
Ezetimibe has one of the cleanest tolerability profiles in cardiology. The most common complaints are mild gastrointestinal symptoms (diarrhea, abdominal pain) and occasional arthralgia, generally indistinguishable from placebo in controlled trials. Muscle symptoms are uncommon and far less frequent than with statins, which is why ezetimibe is the most widely used statin alternative. When combined with a statin, mild ALT elevations are slightly more common than with statin alone, so liver enzymes should be checked at baseline and if symptomatic. Rare post-marketing reports include angioedema, hepatitis, and pancreatitis. The drug is contraindicated in moderate to severe hepatic impairment. Drug interactions are limited - cyclosporine can raise ezetimibe levels significantly, and concomitant fibrates may increase cholelithiasis risk. Pregnancy data are limited; ezetimibe is avoided in pregnancy. Importantly, ezetimibe does not eliminate the underlying need for lifestyle intervention; it complements rather than replaces dietary fat quality, fiber intake, and physical activity.
Practical context
Cost (US, retail)
$10/mo
Legality
FDA-approved; Rx required. Generic available since 2016.
Interactions
false
FAQ
How much does ezetimibe lower LDL?+
Roughly 18-20% LDL-C reduction as monotherapy, with additive effect when combined with a statin (often another 15-20% beyond the statin).
Can ezetimibe replace a statin?+
For statin-intolerant patients, yes - it is the most common alternative. For most others, statin plus ezetimibe is more potent than either alone.
Does ezetimibe cause muscle pain?+
Far less than statins. Most rigorous trials show muscle symptoms similar to placebo. Useful in patients who genuinely cannot tolerate statins.
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.